Literature DB >> 2022408

Red blood cell lithium-sodium countertransport in the tecumseh blood pressure study.

A B Weder1, N J Schork, L Krause, S Julius.   

Abstract

Human essential hypertension has more than one cause, but to dissect out subtypes, markers are required. The maximal activity of red blood cell lithium-sodium countertransport has been shown to be increased in hypertensive patients in case-control and population-based studies; in the latter, its distribution is a mixture of two overlapping but distinguishable subpopulations. In the present study, we classified 705 participants in the Tecumseh Blood Pressure Study as having either normal (mean, 0.234 mmol/l cells/hr; n = 614) or high (mean, 0.463 mmol/l cells/hr; n = 91) red blood cell lithium-sodium countertransport to determine if the red blood cell marker is associated with distinctive physiological characteristics. We found that subjects with elevated lithium-sodium countertransport have higher average blood pressure and a greater prevalence of hypertension than those with normal countertransport and that elevated blood pressure had been present since youth. Hemodynamically, the high countertransport group is characterized by elevated vascular resistance, whereas sympathetic nervous system activity appears to be slightly depressed. Subjects with increased lithium-sodium countertransport, compared with those with normal countertransport, have significantly lower average left ventricular mass index and only very infrequently demonstrate left ventricular hypertrophy. Our results support the usefulness of measurements of the maximal activity of red blood cell lithium-sodium countertransport as a way of distinguishing subgroups in the population. Our data are consistent with the idea that subjects with an elevated maximal activity for red blood cell lithium-sodium countertransport are a subset of the population with a genetic lesion that predisposes them to the development of essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2022408     DOI: 10.1161/01.hyp.17.5.652

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  3 in total

1.  Sodium-lithium countertransport in children with diabetes and their families.

Authors:  P N Houtman; F M Campbell; V Shah; D B Grant; D B Dunger; M J Dillon
Journal:  Arch Dis Child       Date:  1995-02       Impact factor: 3.791

2.  Association of SLC34A2 variation and sodium-lithium countertransport activity in humans and baboons.

Authors:  Xiaojing Zheng; Candace M Kammerer; Laura A Cox; Alanna Morrison; Stephen T Turner; Robert E Ferrell
Journal:  Am J Hypertens       Date:  2009-01-01       Impact factor: 2.689

3.  Association between left ventricular hypertrophy and erythrocyte sodium-lithium exchange in normotensive subjects with and without NIDDM.

Authors:  M J Sampson; E Denver; W J Foyle; D Dawson; J Pinkney; J S Yudkin
Journal:  Diabetologia       Date:  1995-04       Impact factor: 10.122

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.